Motivation-Phase Varenicline

Phase 3Small molecule

VVA Office of Research and Development

Motivation-Phase Varenicline is one of 2 small molecule programs targeting Veterans. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VeteransRecruiting

VeteransPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Veterans

#DrugCompanyPhaseTrials

Motivation-Phase Varenicline

VVA Office of Research and Development

Phase 3

1 2

N-Acetyl Cyteien

SStanford University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

ApprovedRecruiting

Veterans

NCT06966362

Clinical

Trials by Indication[1]

Veterans1 trial

Varenicline for Smoking Reduction in Veterans Unwilling to Quit

Recruiting·VVA Office of Research and Development·Approved·NCT06966362·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Motivation-Phase Varenicline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Motivation-Phase Varenicline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Motivation-Phase Varenicline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VA Office of Research and Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVA Office of Research and Development

Motivation-Phase Varenicline

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Veterans1 trial

References

Drug Info

Quick Facts

Related News